NON-SMALL-CELL LUNG CANCER

This clinical trial compares a new three-drug combination (SYHX2011, carboplatin, and enlonstobart) against the standard three-drug regimen (nab-paclitaxel, carboplatin, and tislelizumab) as a first treatment for people with advanced squamous non-small cell lung cancer. The study…

This Phase 3 trial tests whether adding the experimental drug SYS6010 to standard immunotherapy can better prevent lung cancer from returning after surgery. About 570 adults with stage II-IIIB non-small cell lung cancer who did not respond well to pre-surgery treatment will be ra…

This study tests a new biologic drug called XYA02 in 190 adults with advanced solid tumors (including lung, ovarian, and pancreatic cancers) that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumo…

This Phase 2 trial is testing a drug called firmonertinib for people with a specific type of advanced lung cancer (EGFR-mutated non-small cell lung cancer). The study uses a blood test (ctDNA) to decide if treatment should be adjusted over time. About 154 participants will receiv…

This trial tests an experimental daily pill, VS-7375, for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12D. Participants must have already tried chemotherapy and an immunotherapy drug. The study looks at whether the drug can shri…

This study tests whether adding a new drug called BL-B01D1 to the standard targeted therapy osimertinib can improve outcomes for people with a specific type of lung cancer (EGFR-mutated non-small cell lung cancer) that can be removed with surgery. About 90 participants will recei…

This early-phase trial tests an experimental drug called CLSP-5282 in up to 140 adults with advanced solid tumors (like lung, pancreatic, or colorectal cancer) that have a specific genetic change called KRas G12V. The drug is given by IV infusion. The main goals are to check safe…

This study tests a new drug combination (SYS6010 plus enlonstobart) against the usual immunotherapy with chemotherapy for people with a type of advanced lung cancer that has a specific marker (PD-L1 positive). About 500 adults aged 18-75 who have not had prior treatment for their…

This study tests a new drug called HS-20122 in combination with other cancer medicines for people with advanced non-small cell lung cancer. The trial includes three different drug combinations depending on the patient's tumor type. The main goals are to check safety, find the bes…

This study tests whether the drug divarasib can prevent lung cancer from coming back in people with a specific gene mutation (KRAS G12C) who have already had surgery and chemotherapy. About 400 adults with stage II-III non-small cell lung cancer will be randomly assigned to recei…

This trial tests whether an intelligent breathing exercise device helps people recover lung function after surgery for non-small cell lung cancer. Participants use the device for breathing exercises twice daily for 30 days after surgery, while a comparison group receives standard…

This phase 2 trial tests two different immunotherapy drug combinations (durvalumab with monalizumab or oleclumab) followed by personalized radiation for people with advanced non-small cell lung cancer that has a high PD-L1 score. The goal is to see which combination works better …

This Phase II trial tests a combination of two drugs, trastuzumab rezetecan and ivonescimab, in 30 people with advanced non-small cell lung cancer that has HER2 gene abnormalities. The goal is to see if the combo can control the cancer and delay progression. Participants must hav…

This study tests two treatment plans for people with lung cancer that has spread to the brain but is not causing major symptoms. One group gets focused radiation to all brain tumors first, then a new immunotherapy drug (ivonescimab) plus chemotherapy. The other group gets the imm…

This early-phase study tests two drugs together—navlimetostat and pumitamig—in people with advanced non-small cell lung cancer that has a specific genetic change (MTAP-deficient). The main goal is to find a safe dose and see if the combination helps shrink tumors. About 17 adults…

This study tests whether taking only a few lymph node samples (selective sampling) works as well as removing all nearby lymph nodes (systematic dissection) in people with stage IIA-IIIB non-small cell lung cancer. All participants will first receive chemotherapy combined with imm…

This phase 2 trial tests a new drug called SKB571 combined with other cancer medicines in 150 people with non-small cell lung cancer. The goal is to see if the combination can shrink tumors and control the disease. Participants will receive the drugs by injection or mouth, and re…

This early-stage study tests a new drug called HH160 in about 56 adults with advanced solid tumors (cancers that have spread). The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. Participants will receive HH160 alone or with other cancer tr…

This early-stage trial tests a new drug, AK138D1, alone or with another drug (ivonescimab) in people with advanced non-small cell lung cancer. The goal is to see if the treatment is safe and shrinks tumors. About 265 adults aged 18-75 with stage IIIB/IV cancer will take part.

This study tests whether adding a special type of radiation (SF-SBRT) to the usual combination of immunotherapy (toripalimab) and chemotherapy helps people with stage II-III non-small cell lung cancer live longer without the cancer coming back. About 200 participants will be rand…

This study tests a new drug combination (IBI3005) in about 282 adults with advanced solid tumors that have spread or cannot be removed by surgery. The main goals are to check safety and see if the treatment shrinks tumors. Participants will be closely monitored for side effects a…

This study tests whether giving sintilimab (an immunotherapy drug) together with chemotherapy can shrink advanced stage IIIC lung cancer enough to allow surgery. About 33 adults with previously untreated, unresectable non-small cell lung cancer will receive four cycles of the com…

This early-stage study tests a new drug called JL19001 in people with advanced solid tumors or a type of lymphoma that has come back or not responded to treatment. The main goal is to find a safe dose and check for side effects. About 14 participants will receive the drug as a sh…

This study tests an oral chemotherapy (paclitaxel) combined with immunotherapy given before surgery in patients aged 70-85 with non-small cell lung cancer. The goal is to see if this approach can shrink tumors enough to improve surgery outcomes and long-term survival. About 75 pa…

This early-phase trial tests a new type of cell therapy called TCR1188-ABC for people with certain advanced cancers (pancreatic, colorectal, lung, or bile duct) that have a specific KRAS G12V mutation. The treatment involves taking a patient's own immune cells, engineering them t…

This early-stage trial tests a new drug called JH021 in 60 people with advanced solid tumors that have stopped responding to standard treatments. JH021 is a special antibody that targets two cancer-related proteins, EGFR and cMET, to potentially slow or stop tumor growth. The mai…

This phase 3 trial tests a new type of radiotherapy that uses daily MRI scans to precisely target brain metastases from lung cancer. The approach, called MR-guided adaptive radiotherapy, adjusts the radiation dose based on real-time tumor changes. Researchers hope it will improve…

This early-phase study tests a new drug, CS08399, in people with advanced solid tumors or lymphoma that have a specific gene deletion (MTAP). The main goal is to find a safe dose and understand how the drug works in the body. About 186 participants will take part, and researchers…

This phase 2 trial tests whether combining chidamide (a pill) with ivonescimab (an infusion) can help people with advanced non-small cell lung cancer whose tumors have stopped responding to immunotherapy and have a specific protein marker called YAP. The study will enroll 32 adul…

This phase 2 trial tests whether fecal transplants from immunotherapy responders can improve outcomes in stage II-III non-small cell lung cancer. 68 patients will receive either standard treatment (Durvalumab + chemotherapy) or the same plus fecal transplant capsules. The main go…

This phase 2 study tests whether adding a PCSK-9 inhibitor (recaticimab) to standard immunotherapy and chemotherapy before surgery can improve outcomes for people with resectable non-small cell lung cancer. About 78 participants will receive either adebrelimab or retlirafusp alfa…

This early-stage study tests a new drug called NPX372 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to help the body's immune cells recognize and attack cancer cells. The main goals are to check the drug's safety and fin…

This early-phase trial tests an experimental drug called FXB0871 in about 138 adults with advanced solid tumors, including non-small cell lung cancer and liver cancer, that have stopped responding to standard treatments. The study has two parts: first, finding a safe dose, and se…

This phase II trial tests a new treatment for non-small cell lung cancer using immune cells taken from the patient's own tumor. The cells are grown in a lab and then infused back to attack the cancer. The study will enroll 28 adults and measure how well the treatment shrinks tumo…

This pilot study tests whether it is safe and feasible to skip surgery in patients with stage II-III non-small cell lung cancer who have a complete response to chemotherapy and immunotherapy. Fourteen participants will be randomly assigned to either observation or standard surger…

This phase 2 trial tests a new drug called vebreltinib combined with standard chemotherapy as a first treatment for people with advanced non-small cell lung cancer that has MET overexpression and no other known genetic drivers. The study will enroll 19 participants to see if the …

This phase 2 trial tests whether combining SKB264 (a chemotherapy) with anlotinib (a targeted therapy) can shrink tumors and control disease in people with advanced non-small cell lung cancer that has spread to the liver and stopped responding to standard EGFR-targeted drugs. Abo…

This early-phase study tests an experimental oral drug called KQB368 in 48 adults with advanced solid tumors (like lung, colorectal, or uterine cancer) that have a specific KRAS mutation (G12C or G12S). The main goals are to find a safe dose and see if the drug can shrink tumors.…

This early-phase study tests a new drug called HLX3902 in about 48 people with advanced prostate cancer or other solid tumors that have stopped responding to standard treatments. The main goal is to check the drug's safety and find the best dose. The drug is designed to help the …

This study tests whether combining a targeted drug (furmonertinib) with local treatments like ablation or radiation can help control early-stage non-small cell lung cancer in people who cannot or choose not to have surgery. About 45 participants with specific EGFR gene mutations …

This Phase 2 trial tests two drug combinations for people with a specific genetic mutation (EGFR) in advanced non-small cell lung cancer. One group receives amivantamab plus lazertinib as first treatment; the other gets amivantamab plus chemotherapy after previous treatment stopp…

This Phase 2 trial tests a combination of two drugs, utidelone and bevacizumab, with or without a third drug called etoposide, in 56 patients with brain metastases from lung or breast cancer. The goal is to see if this treatment can shrink brain tumors and improve outcomes. Parti…

This study tests a new treatment called Y-90 FAPI for people with advanced non-small cell lung cancer that has stopped responding to standard therapies. The treatment delivers radiation directly to cancer cells by targeting a protein found on tumor-supporting cells. The goal is t…

This study tests two drugs together for people with advanced non-small cell lung cancer that has HER2 abnormalities. The drugs are SHR-A1811, which targets HER2, and ivonescimab, which boosts the immune system. The goal is to see if the combination can control the cancer longer. …

This early-stage trial tests a new oral drug called HLX97 in 138 people with advanced solid tumors (breast, prostate, or lung cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can slow tumor g…

This study tests a combination of the targeted drug limertinib plus chemotherapy (etoposide and carboplatin) in 30 people with a specific type of lung cancer. These patients have a mutation in the EGFR gene and their cancer has changed from non-small cell to small cell lung cance…

This early-phase study tests a new drug called SYS6090 combined with standard chemotherapy or other drugs in about 600 people with advanced lung cancer (non-small cell or small cell). The goal is to see if the combinations are safe and if they can shrink tumors. The trial is not …

This phase 3 study tests whether a new combination of drugs (HS-20093 plus adebrelimab) works better than the standard chemotherapy docetaxel for people with advanced or metastatic non-squamous non-small cell lung cancer that has already been treated. The trial plans to enroll 45…

This early-stage trial tests a new gene-editing drug called EDB-102 in 15 people with advanced non-small cell lung cancer that has spread to the liver and no longer responds to standard targeted therapy. The drug uses CRISPR technology to target and disable a specific cancer-caus…

This Phase 3 trial compares an experimental drug called SYS6010 with the standard chemotherapy docetaxel in about 506 people with advanced non-squamous non-small cell lung cancer that has not responded to prior treatments. The study aims to see if SYS6010 can slow cancer growth o…

This study tests whether a fecal microbiota transplant (FMT) — transferring healthy gut bacteria from a donor — can help restore the immune system's ability to fight advanced non-small cell lung cancer in 15 patients whose disease worsened after prior immunotherapy. Participants …

This early-stage study tests a new treatment for people with advanced ovarian cancer or other solid tumors that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells that are genetically modified to better recognize and attack cancer…

This early-phase trial tests an experimental drug called ITC-6146RO in about 102 adults with advanced or metastatic cancers (like prostate, lung, or breast cancer) that have not improved with standard treatments. The study has two parts: first, finding a safe dose, then checking …

This early-phase trial is testing a combination of two drugs—izalontamab brengitecan (given by IV) and adagrasib (a pill)—in 18 adults with advanced KRAS G12C-mutant non-small cell lung cancer that has stopped responding to other treatments. The main goal is to check safety and s…

This study looks at whether taking leucogen (a drug that raises white blood cell counts) from the start can prevent low white blood cells in people with RET fusion-positive non-small cell lung cancer who are taking pralsetinib. About 25 people who have not had prior treatment wil…

This early-stage trial is testing a new oral drug called HS-10504 combined with several other drugs given by IV in people with advanced non-small cell lung cancer that has worsened after previous treatment. The study will enroll about 400 participants and aims to find safe doses …

This early-phase study tests a new drug called JSKN027 in 250 adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. The study focuses on colorectal, lun…

This study tests a new way to perform lung cancer surgery using 3D virtual reality models and a special dye that makes lung segments glow during surgery. The goal is to help surgeons remove only the diseased part of the lung more accurately. About 89 adults with early-stage non-s…

This study compares two ways of performing robotic lung surgery for early-stage non-small cell lung cancer. In one method, the surgeon controls all tools from a console (totally robotic). In the other, a bedside assistant helps with handheld staplers. The trial will measure costs…

This study tests a combination of two drugs, SHR-A1811 and pertuzumab, in people with advanced non-small cell lung cancer that has HER2 mutations or overexpression and has worsened after at least one prior treatment. The goal is to see if this combo can shrink tumors or slow dise…

This study tests whether adding the experimental drug plinabulin to standard chemotherapy (docetaxel) helps people with advanced non-squamous lung cancer live longer. It includes about 442 adults whose cancer has worsened despite prior immunotherapy and platinum chemo. Participan…

This early-phase study tests a new drug called QLS5316 in about 300 adults with advanced solid tumors (such as colorectal, stomach, head and neck, or lung cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, a…

This early-phase trial is for people with non-small cell lung cancer that has stopped responding to second-line treatment. Researchers will use a lab test on a patient's own tumor cells to pick the best chemotherapy drugs, then add the statin pitavastatin. The goal is to see if t…

This study tests whether giving the anesthetic lidocaine during lung cancer surgery can reduce the chance of the cancer coming back. About 1,400 patients will be randomly assigned to receive lidocaine or a placebo. They will be followed for three years to track cancer recurrence …

This early-phase trial tests a new therapy called TCR-T cells, which are immune cells engineered to recognize and attack cancer cells with specific KRAS mutations (G12V or G12D). The study will enroll 25 adults with advanced solid tumors (like colorectal or lung cancer) who have …

This phase 2 trial tests the drug golidocitinib in 16 people with advanced lung cancer who have severe blood problems caused by immunotherapy. The goal is to see if the drug can safely improve blood counts and reduce symptoms. Participants take the drug until their blood levels r…

This study tests a new drug called TYK-01054 for people with advanced solid tumors that have not responded to standard treatments. The drug is taken as a capsule and works by blocking a protein (TEAD) involved in cancer growth. The trial will check safety, find the best dose, and…

This study tests two experimental drugs, ANS014004 and PLB1004, given together to people with a specific type of advanced lung cancer (EGFR mutation-positive NSCLC). The goal is to find a safe dose and see if the combination can shrink tumors or stop them from growing, especially…

This study tests whether adding a special type of radiation (quad shot radiotherapy) to a new immunotherapy drug (QL1706) plus chemotherapy can better control advanced non-small cell lung cancer. About 104 people with stage IV lung cancer that has not been treated yet will take p…

This Phase 2 trial tests whether adding SYS6010 to the standard drug osimertinib before surgery can improve outcomes for people with a specific type of lung cancer (EGFR-mutant non-squamous non-small cell lung cancer). About 120 participants with stage II-IIIB disease will receiv…

This phase 2 trial tests a combination of two drugs—HLX43 and serplulimab—in 120 people with advanced lung cancer (non-small cell or small cell). The goal is to see if the combo can shrink tumors and control the disease. Participants must have cancer that has spread or come back …

This Phase 3 trial compares a new drug called JYP0322 with standard platinum-based chemotherapy in 207 people with advanced ROS1-positive non-small cell lung cancer who have already been treated with ROS1-targeted therapy. The main goal is to see if JYP0322 delays cancer growth b…

This study looks at whether surgically removing the primary lung tumor before giving immunotherapy (sintilimab) and chemotherapy can improve outcomes for people with advanced non-small cell lung cancer that is not driven by EGFR or ALK mutations. About 118 participants will be ra…

This study looks at whether surgically removing the primary lung tumor before starting the targeted drug osimertinib can help people with advanced EGFR-mutant non-small cell lung cancer. About 118 patients with stage III-IV cancer will be randomly assigned to get surgery plus osi…

This study tests a drug called AK112 in 60 people with a certain type of advanced lung cancer (non-squamous non-small cell lung cancer) that has specific genetic changes and has stopped responding to previous targeted therapy. The main goal is to see how many patients' tumors shr…

This study tests a new drug called CVL006 combined with standard chemotherapy or other targeted drugs in people with advanced solid tumors that have not responded to previous treatments. The trial has two phases: first, to find the safest dose, and second, to see if the combinati…

This study tests whether a new MRI contrast agent, gadopiclenol, can detect brain metastases earlier than standard methods in 180 patients with advanced lung, breast, or skin cancer. Participants will receive screening brain MRIs to compare diagnosis timing and accuracy. The goal…

This early study tests a new radioactive antibody called NTH-2403 in 16 people with advanced colorectal, head and neck, lung, or triple-negative breast cancers. The antibody targets a protein found on cancer cells and their supporting cells, allowing doctors to see tumors on scan…

This study looks at whether low-dose CT scans can help find lung cancer early in people aged 40 to 80 who have never smoked. About 2,500 participants will fill out questionnaires, give blood and urine samples, and have lung function tests and CT scans. Researchers will track how …

This study compares 3D models from non-contrast CT scans to standard contrast CT scans for planning minimally invasive lung cancer surgery. Researchers will check if the 3D models accurately show blood vessels, airways, and tumor location during surgery. If they work, patients mi…

This study tests whether electroacupuncture (using mild electric pulses on needles) plus tiny thumbtack needles can prevent nerve damage caused by chemotherapy in people with early-stage cancer. About 278 patients with breast, stomach, bowel, lung, or ovarian cancer will receive …

This study looks at whether the shingles vaccine can prevent shingles and improve survival in 500 lung cancer patients. Participants will either receive the vaccine or not, and researchers will track shingles cases and survival rates over time. The goal is to see if the vaccine o…

This study tests a smart breathing exercise device for people recovering from lung cancer surgery. About 200 adults will either use the device for 30 days after surgery or receive standard care. The goal is to see if the device improves lung function, reduces shortness of breath,…

This study tests whether a home-based exercise program can help people with gastrointestinal or lung cancer handle chemotherapy better. Up to 120 participants will be randomly assigned to either an aerobic and resistance exercise group or a stretching group. All activities are do…

This study tests a LINE chatbot that gives visual, interactive tips to help lung cancer patients handle side effects from their targeted therapy. About 178 adults with advanced lung cancer will either get usual care or also access the chatbot. The goal is to see if the chatbot bo…

This study tests whether a liquid form of megestrol acetate (a drug that stimulates appetite) can help malnourished people with non-small cell lung cancer gain weight while they receive standard chemotherapy. About 116 participants will be randomly assigned to get either the drug…

This pilot study tests whether a personalized exercise program is practical for 20 adults with stage II or III non-small cell lung cancer who are about to start treatment. Participants will follow the Precise Exercise Regimen for Cancer Care (PERCC) program before and after their…

This study looks at whether a two-week program of walking and breathing exercises before surgery for non-small cell lung cancer can help reduce pain, speed up recovery, shorten hospital stays, and improve quality of life. About 62 adults scheduled for surgery will be split into t…

This early study tests whether selpercatinib, a drug already used for certain cancers, can help with cachexia (severe weight loss and appetite loss) in people with advanced lung, colon, or pancreatic cancer. Seven participants will take the drug twice daily for 12 weeks, with reg…

This study explores whether a hair follicle or cheek swab can accurately measure a person's internal body clock (circadian rhythm) in patients with advanced lung cancer receiving immunotherapy. Researchers will use a new tool called TimeTeller to analyze gene activity from these …

This study involves 3,400 people with advanced non-small cell lung cancer to see if a new test for a protein called TROP2 works consistently across different laboratories. The goal is to ensure that doctors can reliably use this test to guide treatment decisions. Participants pro…

This study looks at whether getting immunotherapy infusions in the morning versus the afternoon changes outcomes for people with advanced lung cancer or head and neck cancer. About 238 participants will be randomly assigned to morning or afternoon infusions. Researchers will trac…

This study watches how well the drug repotrectinib works and what side effects it causes in Korean patients with a specific type of lung cancer or solid tumors that have certain gene changes. About 10 patients will be followed for up to 12 months during their normal treatment. Th…

This observational study will follow about 2,000 patients in China who have early-stage lung cancer with a specific gene mutation (EGFR) and have received targeted therapy pills (EGFR-TKIs) after surgery. Researchers will track how long patients live and how long they stay cancer…

This study tests whether a special headset (extended reality) can help surgeons plan the removal of cancer-affected lymph nodes in the neck for people with lung cancer. Ten patients will have their PET and CT scans combined into a 3D model that the surgeon views just before surge…

This study interviews about 85 patients with early-stage non-small cell lung cancer and 15 doctors to find out what makes it hard or easy to keep taking the drug osimertinib after surgery. The goal is to identify barriers like side effects, cost, or communication issues, and faci…

This early-stage study looks at whether taking oral paclitaxel with encequidar on an empty stomach or after a meal changes how much drug gets into the body. About 46 adults with advanced solid tumors (like breast, lung, or stomach cancer) will take the drugs in different sequence…

This study will collect tumor samples and medical data from 150 adults with non-small cell lung cancer (stages I to IV) at Bordeaux University Hospital. Researchers will analyze the molecular, metabolic, and immune features of the tumors to understand how the cancer progresses an…

This study will follow 600 people with early-stage solid cancers (like lung, head and neck, melanoma, or bladder cancer) who are receiving immunotherapy before surgery. Researchers will collect blood and tumor samples at several time points to see how the immune system responds. …

This early study tests whether applying low-intensity electric fields (TTFields) to the chest before lung cancer surgery is safe and affects cancer-related genes. About 18 adults with stage I-IIIA non-small cell lung cancer will wear a non-invasive device for a short time before …

This study aims to see if changes in certain immune cells in the blood can predict how well advanced lung cancer patients respond to a combination of chemotherapy and immunotherapy. About 80 adults with stage IIIB or IV non-small cell lung cancer will give blood samples before an…

This study looks at whether tiny particles in the blood, called extracellular vesicles, can help doctors predict if immunotherapy will work for people with advanced lung cancer or melanoma. Researchers will collect blood samples from 378 patients before and during standard treatm…

This study looks at whether a blood test for circulating tumor DNA (ctDNA) can detect leftover cancer after surgery in people with breast, lung, prostate, ovarian, or stomach cancer. About 840 participants will give blood samples before and after standard treatments. No new treat…

This study will measure specific immune cells in the blood of 200 non-small cell lung cancer patients before and after surgery. The goal is to see if these markers can help predict if the cancer will come back or how long patients will live. Participants must have early-stage lun…

This study will observe 300 people with advanced lung or gastrointestinal cancers who receive adebrelimab combined with other treatments. Researchers will track side effects and how well the cancer responds. It is a real-world study, meaning it watches what happens in regular med…